DongKook Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 14, 2022 at 08:26 am
Share
DongKook Pharmaceutical Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was KRW 5,387.57 million compared to KRW 4,049.32 million a year ago. Net income was KRW 11,816.95 million compared to KRW 8,484.03 million a year ago. Basic earnings per share from continuing operations was KRW 269 compared to KRW 193 a year ago. Diluted earnings per share from continuing operations was KRW 264 compared to KRW 190 a year ago. Basic earnings per share was KRW 269 compared to KRW 193 a year ago. Diluted earnings per share was KRW 264 compared to KRW 190 a year ago.
For the nine months, sales was KRW 17,468.61 million compared to KRW 10,707.37 million a year ago. Net income was KRW 43,531.34 million compared to KRW 34,933.13 million a year ago. Basic earnings per share from continuing operations was KRW 990 compared to KRW 795 a year ago. Diluted earnings per share from continuing operations was KRW 973 compared to KRW 781 a year ago. Basic earnings per share was KRW 990 compared to KRW 795 a year ago. Diluted earnings per share was KRW 973 compared to KRW 781 a year ago.
DongKook Pharmaceutical Co., Ltd. is a Korea-based company engaged in the development, manufacture and distribution of pharmaceuticals. The Company develops and provides remedies for oral troubles, skin troubles and gynecology diseases, contrast mediums, anesthetics, anticancer medicines and circulatory system agents. It also provides other pharmaceuticals, such as remedies for arthritis and pancreatitis, antiphlogistic, anodynes, antibiotics and vitamins, as well as raw materials for pharmaceuticals. In addition, it is engaged in the rental business. The Company distributes its products within domestic market and to overseas markets, such as Japan, Germany, India, Brazil and Mexico, among others.